Efficacy and safety of Ayurveda Formulation â??Trikatuâ?? as add-on to standard care in Dyslipidemia- A Randomized Controlled Trial

Central Council for Research in Ayurvedic Sciences Ministry of Ayush Govt of India0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

研究概览

暂无简介。

•1. Diagnosis of moderate and high ASCVD risk dyslipidemia based on the ACC/AHA Guidelines, 2019 on the Primary Prevention of Cardiovascular Disease and indicated for statin therapy
•2.Body Mass Index (BMI) >= 18.5 and < 34.9 kg/mÂ².
•3. Written informed consent provided prior to screening, after receiving and understanding the subject information.
•4. Willingness to adhere to the treatment for a period of 12 weeks

•1. Subjects on any lipid altering drug therapy other than statins
•2. Patients of dyslipidemia with low ASCVD risk as per the ACC/AHA guidelines, 2019 and not indicated for statin therapy
•3. Subject using or were using the following medications: systemic corticosteroids, cyclical or non-continuous hormone therapy (estrogen or testosterone). within 6 weeks prior to screening
•4. Pregnant, lactating mother, Smoker, alcoholic
•5. Severe liver and kidney disease, Myopathies
•6. Any other condition, that as per the PI would jeopardize the study/ study outcomes

发起方

Central Council for Research in Ayurvedic Sciences Ministry of Ayush Govt of India